PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Issue 1 (February 2022)

• Record Type: Journal Article
• Authors: Minari, Roberta; Bonatti, Francesco; Mazzaschi, Giulia; Dodi, Alessandra; Facchinetti, Francesco; Gelsomino, Francesco; Cinquegrani, Gloria; Squadrilli, Anna; Bordi, Paola; Buti, Sebastiano; Bersanelli, Melissa; Leonetti, Alessandro; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Quaini, Federico; Ardizzoni, Andrea; Tiseo, Marcello
• Is Part Of: Tumori. Volume 108:Issue 1(2022)
• Page Start: 47
• Page End: 55
• Publication Date: 2022-02
• Subjects: NSCLC -- immunotherapy -- PD-L1 -- SNPs -- biomarker; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916211014954
• Languages: English
• ISSNs: 0300-8916

Abstract

Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association ( p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype ( p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.